-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RV4Y0QGAUo+ZJGdZcSyQCWfpfqpcZJkDc4YtEu0D8GV8s9PJFt3qVRNFsMpPPZJW q7hdzH2Wurv7lXU/z35rBQ== 0001104659-10-005052.txt : 20100205 0001104659-10-005052.hdr.sgml : 20100205 20100205080131 ACCESSION NUMBER: 0001104659-10-005052 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20100204 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20100205 DATE AS OF CHANGE: 20100205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 10575679 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 8-K 1 a10-3190_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported):  February 4, 2010

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-30833

 

04-3110160

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 


 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 of the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

 

 

 



 

Item 2.02               Results of Operations and Financial Condition.

 

On February 4, 2010, Bruker Corporation issued a press release announcing management promotions as well as selected preliminary financial results for the three months ended December 31, 2009.  A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in the preceding paragraph, as well as Exhibit 99.1 referenced therein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01.              Financial Statements and Exhibits.

 

(d)      Exhibits

 

Number

 

 

 

 

 

99.1

 

Press release dated February 4, 2010.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION

 

(Registrant)

 

 

 

Date: February 4, 2010

By:

/s/Frank H. Laukien

 

 

Frank H. Laukien, Ph.D.

 

 

Chief Executive Officer and President

 

3


EX-99.1 2 a10-3190_1ex99d1.htm EX-99.1

Exhibit 99.1

 

Bruker Announces Management Promotions and Strong Fourth Quarter 2009 Preliminary Operating Results

 

BILLERICA, Mass. — February 4, 2010 — Bruker Corporation (NASDAQ: BRKR) this week made certain management changes effective, and today announces strong preliminary operating results for its fourth quarter, which ended on December 31, 2009.

 

Management Promotions Effective February 2010

 

As previously announced, effective February 1st, 2010 William Knight, formerly Bruker’s Chief Financial Officer, became the Company’s Chief Operating Officer.  Mr. Knight was succeeded as Chief Financial Officer by Brian Monahan, previously the Company’s Vice President of Finance.  In addition, Drs. Werner Maas and Bernd Gewiese were promoted to Co-Presidents of Bruker’s BioSpin division, also effective as of February 1st, 2010.

 

Frank Laukien, President and CEO of Bruker Corporation, commented: “Bruker is fortunate to have outstanding and strongly committed management talent within the Company, and we are very pleased to develop our organization further with such excellent internal candidates.  On behalf of the entire Company, I wish Bill, Brian, Werner and Bernd much success in continuing to drive Bruker as a customer-oriented, innovative provider of high-performance scientific instruments and analytical solutions.”

 

Fourth Quarter 2009 Preliminary Operating Highlights

 

Bruker intends to announce its fourth quarter (Q4) of 2009 and full year 2009 financial results on February 25, 2010.  The Company’s preliminary, unaudited operating results for the fourth quarter of 2009 have significantly exceeded previous expectations.

 

For Q4 of 2009:

 

·                  total Bruker revenue is now estimated to be greater than $355 million (on January 13, 2010, the Company had estimated Q4 revenue of greater than $340 million)

 

·                  the Bruker Scientific Instruments (BSI) segment expects a GAAP operating margin of greater than 18%

 

·                  the Bruker Energy & Supercon Technologies (BEST) segment estimates revenue at greater than $20 million, with year-over-year growth greater than 75%, and BEST also anticipates a reduced operating loss year-over-year

 

The Company’s fourth quarter 2009 financial highlights provided above are preliminary and do not present all information necessary for an understanding of the Company’s 2009 financial position and results of operations.  Moreover, the full year 2009 financial results are currently being audited by the Company’s independent registered public accounting firm.  The Company’s completion of its 2009 financial statements, and the related audit of these financial statements, could result in material changes to the preliminary financial results stated above.

 



 

ABOUT BRUKER CORPORATION

 

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation, please visit www.bruker.com.

 

CAUTIONARY STATEMENT

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties, that could cause actual future results to differ materially from those projected including, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

 

FOR FURTHER INFORMATION:

Stacey Desrochers, Director of Investor Relations

 

Tel: +1 (978) 663-3660, ext. 1115

 

Email:  stacey.desrochers@bruker.com

 

2


-----END PRIVACY-ENHANCED MESSAGE-----